New York, May 29, 2026, 05:04 EDT
- Synergy CHC traded at $0.253 ahead of the open, after ending Thursday at $0.2782, a gain of 10.57%.
- Volume jumped Thursday to roughly 116.2 million shares, well above the stock’s usual trading levels.
- Investors are looking at a Nasdaq bid-price warning, a new resale registration now in effect, and a soft first-quarter report.
Synergy CHC Corp. shares dropped in early premarket trading Friday, retracing some of Thursday’s big rally that pushed the lightly traded consumer-health stock back into focus for traders.
Synergy shares traded at $0.253 in premarket action, down 9.06% as of 4:58 a.m. EDT. Premarket moves show trades before the Nasdaq opens at 9:30 a.m. and closes at 4 p.m. The stock closed Thursday at $0.2782, gaining 10.57%.
Synergy saw heavier than usual trading on Thursday, with about 116.2 million shares changing hands. That followed trades in just the hundreds of thousands on May 26 and May 27. The stock hit $0.38 at one point, then ended the day under 30 cents.
Investors saw a new financing setup after the SEC made effective a Synergy Form S-1 registration statement for Hudson Global Ventures on May 22, a notice of effectiveness said.
Hudson plans to sell up to 101.7 million shares, according to the S-1 filing. The document details an equity line of credit that gives Synergy the option to sell shares to an investor over time if certain terms are hit. Synergy said it could get as much as $36 million in gross proceeds through the deal, but it will not see any proceeds from Hudson’s sale of shares that are already registered.
Synergy’s filing states it can tell Hudson to buy shares at any time over about 24 months, but only within certain limits and depending on market conditions. It also warns that selling a large chunk of registered stock could push down the market price and lead to “substantial dilution.” That means existing holders could end up with a smaller stake in the company after more shares hit the market.
Synergy is working to fix a Nasdaq listing snag after getting a notice on May 15 that its closing bid had stayed under $1 for 30 straight business days. The company now has until November 11 to get its closing price to $1 or more for at least 10 days in a row to regain compliance. The filing said the notice does not affect trading right now.
Synergy’s fundamentals offered little support. First-quarter revenue came in at $5.49 million, down from $8.17 million one year ago. The company posted a net loss of $2.57 million, reversing net income of $0.88 million for the same stretch last year. CEO Jack Ross called it a quarter of “continued execution and the growing momentum” for the functional beverage business.
The company reported beverage revenue of more than $650,000 for the quarter, beating its total beverage revenue for all of 2025. But the balance sheet stayed tight. It had $292,115 in cash and cash equivalents as of March 31. Long-term notes payable were about $25.0 million, with another $2.7 million in current notes payable.
Synergy is moving into a packed beverage space. In its S-1, it names Celsius and Monster as big players in the energy and functional-drink market, but the difference in size is big. Early Friday, Celsius was valued at about $8.6 billion and Monster at about $87.0 billion. Synergy’s own market value is about $3.1 million.
S&P 500 rose 0.6% and the Nasdaq gained 0.9% on Thursday, per AP. The tape leaned higher, but Synergy traded more like a microcap story than an index move. Microcap means a company with a small market cap.
The risk is clear. If the stock keeps trading well below $1, Synergy may have to go for a reverse split to boost its share price, or else it could land in a delisting process. Drawing on the Hudson facility could also mean issuing new shares, which would dilute current holders while Synergy is already dealing with losses, debt, and low cash.
Friday brings a test for the stock: can it hold the premarket drop, or does Thursday’s spike in volume bring retail buyers back in? Next week hinges on filings, possible news about the financing line, and if shares can move up toward Nasdaq’s $1 level.
